Guidant Returns to CRT-D Market With New Supplier For Problem Component
This article was originally published in The Gray Sheet
Executive Summary
Guidant expects to fully re-supply U.S. customers with Contak Renewal 3 cardiac resynchronization implantable defibrillators (CRT-D) by the end of August, following FDA approval to re-launch the device